BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M

BIOLIFE SOLUTIONS INC

2025-Q2 EPS reported -$0.34 revenue$49,362,000

Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
GAAP net loss $15.8M includes non-cash $15.5M IPR&D charge from PanTHERA acquisition.
Non-GAAP adjusted net income $0.5M vs. loss of $1.0M a year ago; adjusted EBITDA $6.1M (24% of revenue).
Raises FY2025 Cell Processing revenue guidance to $91-93M; total revenue guidance to $100-103M.
Biopreservation media embedded in 16 approved therapies; over 250 ongoing trials, including 30+ Phase III.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.